Akihiko Koshino

Dapagliflozin and Anemia in Patients with Chronic Kidney Disease

Akihiko Koshino, Meir Schechter, Glenn M. Chertow et al. · NEJM Evidence · 2023 · 67 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

Akihiko Koshino, Meir Schechter, Taha Sen et al. · Diabetes Care · 2022 · 58 citations · Full text

Medicine, Immunology, Internal Medicine +17

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

Akihiko Koshino, Brendon L. Neuen, Niels Jongs et al. · Cardiovascular Diabetology · 2023 · 30 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Mechanisms of action of the sodium‐glucose cotransporter‐2 ( <scp>SGLT2)</scp> inhibitor canagliflozin on tubular inflammation and damage: A <i>post hoc mediation</i> analysis of the <scp>CANVAS</scp> trial

Taha Sen, Akihiko Koshino, Bruce Neal et al. · Diabetes Obesity and Metabolism · 2022 · 27 citations · Full text

Medicine, Nephrology, Pharmacology +17

Clinical and Pathological Significance of Autoantibodies to Erythropoietin Receptor in Type 2 Diabetic Patients With CKD

Akinori Hara, Kengo Furuichi, Akihiko Koshino et al. · Kidney International Reports · 2017 · 14 citations · Full text

Medicine, Endocrinology, Nephrology +12